First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik(South Texas Accelerated Research Therapeutics), Leonard J. Appleman(University of Pittsburgh), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Kyriakos P. Papadopoulos(South Texas Accelerated Research Therapeutics), Muralidhar Beeram(South Texas Accelerated Research Therapeutics), Drew Rasco(South Texas Accelerated Research Therapeutics), Glen J. Weiss(Cancer Treatment Centers of America), Jasgit C. Sachdev(Translational Genomics Research Institute), Manpreet Chadha(Translational Genomics Research Institute), Maddie Fulk(Translational Genomics Research Institute), Samuel Ejadi(Translational Genomics Research Institute), James M. Mountz(University of Pittsburgh), Michael T. Lotze(University of Pittsburgh), Frederico G. S. Toledo(University of Pittsburgh), Edward Chu(University of Pittsburgh), Michael Jeffers(Bayer (United States)), Carol E. Peña(Bayer (United States)), Chenjing Xia(Bayer (United States)), Stefanie Reif(Bayer (Germany)), Isabelle Genvresse(Bayer (Germany)), Ramesh K. Ramanathan(Translational Genomics Research Institute)
Cited by 236Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis